The AZD1222 vaccine (Astrazeneca, Cambridge, UK) is effective and safe against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1. In real-life experience, cases of vaccine-induced thrombocytopenia and thrombosis (VITT) have been described, with associated high morbidity and mortality rates. Thrombocytopenia and thrombosis in unusual venous sites are the common clinical presentation, but arterial thrombosis has also been described2,3. Some treatment recommendations have been published4. Plasma exchange (PE) has recently been reported to be effective in three patients5. We discuss the case of a patient successfully treated with PE after a severe VITT with atypical arterial involvement.
- Abstract viewed - 53 times
- PDF downloaded - 1 times